Evidence map›Paper›PMID 41331401›Full record

ArticleDiscover oncology2025

Effects of beta-cyclodextrin-Combretastatin A-4 nanoparticles containing selenium on apoptosis and metastasis of U-87MG glioblastoma cancer cells.

Seyedeh Motahareh Hosseini, Fatemehsadat Hosseini, Elaheh Gheybi, Elham Einafshar, Ebrahim Eftekhar, Mahmood Khayatian, Mohammad Soukhtanloo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Seyedeh Motahareh HosseiniMolecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Fatemehsadat HosseiniDepartment of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad, Iran.
Elaheh GheybiDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Elham EinafsharPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran.
Ebrahim EftekharMolecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Mahmood KhayatianMolecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Kayatian@yahoo.com.
Mohammad SoukhtanlooPharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran. soukhtanloom@mums.ac.ir.

Funding

Hormozgan University of Medical Sciences 4020600
6 · The paper itself

Abstract

backgroundGlioblastoma (GBM), the most aggressive primary brain tumor, faces significant treatment challenges due to drug resistance, blood-brain barrier limitations, and severe side effects of conventional therapies. This study aimed to develop and evaluate a nanotechnology-based therapeutic approach using selenium-loaded β-cyclodextrin-combretastatin A-4 nanoparticles (Se(B-CD-CA-4-NPs)) to overcome these limitations and enhance treatment efficacy.

methodsThe Se(B-CD-CA-4-NPs) complex was synthesized and characterized for morphology, size, stability, and selenium loading capacity. In vitro studies included MTT assay, cell apoptosis, scratch assay, gelatin zymography, and qPCR were used to assess the effect of the newly synthesized complex on U-87MG glioblastoma cell viability, cell death, migration, MMP-2 and MMP-9 activity, and mRNA expression level of apoptosis-related genes.

resultsThe nanoparticles exhibited a spherical morphology (25.78 ± 3.4 nm), negative surface charge, and high stability. The IC

conclusionThe Se(B-CD-CA-4-NPs) complex represents a promising multifunctional therapeutic agent for GBM, offering enhanced proapoptotic property, selective tumor targeting, and reduced toxicity.

Indexed as

ApoptosisGlioblastomaMetastasisMMPsSe(B-CD-CA-4-NPs) complex

Identifiers

PMID41331401
PMCPMC12775192

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.